Summary
Updated Aug 31, 2026
Robert Azelby is Director of Autolus Therapeutics plc (AUTL). 7 SEC Form 4 filings on record going back to 2024, most recently on 1 July 2026.
Recent Transactions
5Every recent SEC Form 4 transaction Robert Azelby has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Robert Azelby files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Redmile Group, LLC - $49.64M of ADCT open-market activity in the last 12 months
- Third Rock Ventures IV, L.P. - $16.52M of TNGX open-market activity in the last 12 months
- Adam Crystal - $5.72M of TNGX open-market activity in the last 12 months
- Barbara Weber - $374K of TNGX open-market activity in the last 12 months
- Daniella Beckman - $127K of TNGX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Robert Azelby?
Robert Azelby is a corporate insider, tracked as Director of Autolus Therapeutics plc (AUTL). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Robert Azelby submitted recently?
3 primary Form 4 filings in the last 90 days, covering 3 companies.
Where can I see all of Robert Azelby's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Robert Azelby and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
